Community Member Nominations Are Now Being Accepted for the Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for a new community representative to serve a 4-year term beginning May 2017 with potential for reappointment for one additional term. The Panel welcomes diversified representation in the community membership reflecting the demographics of the current HIV epidemics in the United States. The community member may assist the Panel in identifying and addressing unique treatment aspects that relate to the constituency he/she represents. The candidate shall have knowledge and involvement in issues related to management of HIV-infected adults and adolescents, as evidenced by experience in HIV treatment education/advocacy or clinical/public policy initiatives related to HIV treatment.
The Panel is a Working Group of the Office of AIDS Research Advisory Counsel of the National Institutes of Health. The Panel is composed of over 40 members who are clinicians, researchers, academicians, HHS representatives, and community representatives with expertise in HIV management in the United States. The Panel meets monthly via teleconferencing and annually in a face-to-face meeting to review and critically evaluate emerging scientific data relating to antiretroviral therapy and to revise the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. The guideline is a living document that can be found at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines. The last revision was released on July 14, 2016.
Panel members are not compensated for their time commitment.
The nomination should include a resume and a letter of nomination or a letter of interest with specific reference as to how the nominee would contribute to the work of the Panel. Self-nomination is welcome. All supporting documents should be submitted to Alice Pau, Pharm.D. electronically (email@example.com) by no later than February 10, 2017.